IDEAYA Biosciences (IDYA) Cash & Equivalents (2018 - 2026)

IDEAYA Biosciences has disclosed Cash & Equivalents across 9 years of filings, most recently posting $157.5 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $157.5 million, up 21.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $157.5 million (up 21.17% YoY), and the FY2025 annual result was $112.8 million, up 33.71% from the prior year.
• Cash & Equivalents came in at $157.5 million for Q1 2026 at IDEAYA Biosciences, up from $112.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $400.3 million in Q3 2024 to a low of $49.1 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $112.8 million (2025), against an average of $137.9 million.
• Across the five-year window, Cash & Equivalents sank 59.57% in 2022 and surged 163.6% in 2024, its largest moves.
• IDEAYA Biosciences' Cash & Equivalents stood at $68.6 million in 2022, then jumped by 128.78% to $157.0 million in 2023, then sank by 46.26% to $84.4 million in 2024, then soared by 33.71% to $112.8 million in 2025, then surged by 39.62% to $157.5 million in 2026.
• The last three Cash & Equivalents figures came in at $157.5 million (Q1 2026), $112.8 million (Q4 2025), and $298.9 million (Q3 2025), per Business Quant data.